AHMEDABAD, India, Aug. 6, 2025 /PRNewswire/ -- Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has…
AHMEDABAD, India, Aug. 5, 2025 /PRNewswire/ -- Intas Pharmaceuticals has launched HETRONIFLY™ (Serplulimab), the first PD-1 inhibitor globally approved for…
August 01, 2025 16:55 ET | Source: Xenon Pharmaceuticals Inc. VANCOUVER, British Columbia and BOSTON, Aug. 01, 2025 (GLOBE NEWSWIRE)…
License agreement supports Madrigal’s pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra™ (resmetirom)…
July 16, 2025 16:05 ET | Source: Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals,…
- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data from Phase…
July 10, 2025 16:28 ET | Source: Crinetics Pharmaceuticals, Inc. SAN DIEGO, July 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals,…
July 09, 2025 16:16 ET | Source: Rhythm Pharmaceuticals, Inc. BOSTON, July 09, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc.…
Signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852Continue enrolling patients in Phase 2 study of…
June 23, 2025 16:50 ET | Source: Scilex Holding Company PALO ALTO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Scilex…